# Molecularly Tailored Therapy to Standard of Care as Second-Line Therapy in Metastatic Pancreatic Cancer

> **NCT02967770** · PHASE2 · WITHDRAWN · sponsor: **Georgetown University**

## Conditions studied

- Metastatic Pancreatic Cancer

## Interventions

- **OTHER:** Molecularly Tailored Second Line Therapy
- **DRUG:** Standard of Care Second Line Therapy

## Key facts

- **NCT ID:** NCT02967770
- **Lead sponsor:** Georgetown University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-11
- **Primary completion:** 2018-08-30
- **Final completion:** 2018-08-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Issues with patient recruitment.
- **Last updated:** 2018-09-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02967770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02967770, "Molecularly Tailored Therapy to Standard of Care as Second-Line Therapy in Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02967770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*